The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

Abridge achieves deep user personalization beyond simple stylistic preferences. It operates at three levels: the individual doctor's phrasing, the specific requirements of a medical specialty (e.g., cardiology), and the unique best-practice guidelines of an entire hospital system, making the tool feel indispensable to all stakeholders.

Treat AI initiatives as two separate strategic pillars. Create one roadmap focused on internal efficiency gains and cost reduction (productivity). Maintain a separate roadmap for developing new, revenue-generating customer experiences (growth). This prevents conflating internal tools with external products.

Bill Glenn suggests a phased AI rollout for teams. Phase 1 focuses on efficiency and automating repeatable tasks to gain productivity. Phase 2 moves to strategic work, using AI for insights and decision-making assistance. This provides a clear, manageable roadmap for adoption.

While proprietary data and high-quality models are important, Abridge's true moat lies in its deep integration into the clinical workflow. By solving problems like prior authorization in real-time while the patient is still in the room, it collapses weeks of administrative latency into minutes, creating value that is hard to replicate.

To find valuable AI use cases, start with projects that save time (efficiency gains). Next, focus on improving the quality of existing outputs. Finally, pursue entirely new capabilities that were previously impossible, creating a roadmap from immediate to transformative value.

Chronic disease patients face a cascade of interconnected problems: pre-authorizations, pharmacy stockouts, and incomprehensible insurance rules. AI's potential lies in acting as an intelligent agent to navigate this complex, fragmented system on behalf of the patient, reducing waste and improving outcomes.

The most tangible ROI for AI in healthcare today isn't in complex diagnostics, but in operational efficiency. AI scribes that free up doctors, intelligent call centers that triage patients correctly, and automated claim management are solving major bottlenecks and fighting burnout right now.

To avoid the "alert fatigue" common in medical software, Abridge's product philosophy is for its AI to be proactive, not reactive. It works seamlessly in the background to prepare clinicians before visits, rather than interrupting them with constant alerts during patient conversations, making the experience helpful but unobtrusive.